Crestor and strong non-US growth settle AstraZeneca
This article was originally published in Scrip
Executive Summary
AstraZeneca reported that strong revenue growth in non-US markets during 2010 offset the loss of more than $1.6 billion of US revenue from generic competition on several products and the absence of H1N1 pandemic influenza vaccine revenue. Higher sales of the cholesterol treatment Crestor, in particular, kept full year revenues flat at $33.3 billion.